Validation of cleaning procedures for highly potent drugs. II. Bisnafide

Pharmaceutical Development and Technology

Volumn 3, Issue 4, 1998, Pages 471-476

  Segretario, James ^a   Cook, Stacy C ^a   Umbles, Cheryl L ^a   Walker, Joanne T ^a   Woodeshick, Robert W ^a   Rubino, Joseph T ^b   Shea, James A ^a  

^a DUPONT COMPANY   (United States)

^b PFIZER INC   (United States)

Author keywords

Antineoplastic agents; Bisnafide; Cleaning validation; HPLC

Indexed keywords

ACETIC ACID; BISNAFIDE MESYLATE; GLASS; STAINLESS STEEL; WATER;

ARTICLE; CLEANING; DRUG CONTAMINATION; DRUG MANUFACTURE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; PRIORITY JOURNAL; REPRODUCIBILITY; VALIDATION PROCESS;

EID: 0031796820     PISSN: 10837450     EISSN: None     Source Type: Journal    
DOI: 10.3109/10837459809028628     Document Type: Article

References (18)

1. P. W. Cobb, D. R. Degen, G. M. Clark, S. F. Chen, J. G. Kuhn, J. L. Gross, M. R. Kirshenbaum, J. H. Sun, H. A. Burris III, et al., Activity of DMP 840, a new bis-naphthalimide, on primary human tumor colony-forming units, J. Natl. Cancer Inst., 86(19), 1462-1465 (1994).
2. P. J. Houghton, P. J. Cheshire, J. C. Hallman III, J. L. Gross, R. J. McRipley, J. H. Sun, C. H. Behrens, D. L. Dexter, and J. A. Houghton, Evaluation of a novel bisnaphthalimide anticancer agent, DMP 840, against human xenografts derived from adult, juvenile, and pediatric cancers, Cancer Chemother. Pharmacol., 33(4), 265-272 (1994).
3. M R. Kirshenbaum, S. F. Chen, C. H. Behrens, L. M. Papp, M. M. Stafford, J. H. Sun, D. L. Behrens, J. R. Fredericks, S. T. Polkus, et al., (R,R)-2,2'-[1,2-ethanediylbis[imino(1 - methyl -2,1- ethanediyl)]] - bis[5 - nitro - 1H-benz[de]isoquinoline-1,3-(2H)-dione] dimethanesul-fonate (DMP 840), a novel bis-naphthalimide with potent nonselective tumoricidal activity in vitro, Cancer Res., 54(8), 2199-2206 (1994).
4. P. J. Houghton, P. J. Cheshire, J. Hallman, J. H. Sun, C. H. Behrens, and R. McRipley, Evaluation of DMP 840, A novel anti-tumor agent in xenografts derived from adult and childhood malignancies, Proc. Am. Assoc. Cancer Res., 84th Meeting, 368 (1993).
5. R. B. Mitchell, G. Goss, M. Guarino, M. Keaton, N. Hammond, M. Finizio, and J. Gray, Phase II trial of bisnafide in advanced non-small cell lung cancer (NSCLC), Proc. Am. Soc. Clin. Oncol., 15, 32nd Meeting, 404 (1996).
6. R. C. Kline, D. Melnychuk, M. Schiano, K. Reynolds, M. F. K. Fung, M. A. Finan, M. Finizio, and J. Gray, A phase II multicenter clinical trial of bisnafide in women with advanced refractory ovarian carcinoma, Proc. Am. Soc. Clin. Oncol., 15, 32nd Meeting, 293 (1996).
7. J. Maroun, M. Guarino, R. Goel, C. Cripps, M. Finizio, and J. Gray, Phase II trial of bisnafide (B) in untreated patients with colorectal cancer (CRC), Proc. Am. Soc. Clin. Oncol., 15, 32nd Meeting, 219 (1996).
8. H. L. Avallone, Drug substance manufacture and control, Pharm. Eng., 9(2), 37-40, 57 (1989).
9. S. W. Harder, The validation of cleaning procedures, Pharm. Technol., 8(5), 29-34 (1984).
10. D. W. Mendenhall, Cleaning validation, Drug Dev. Ind. Pharm., 15(13), 2105-2114 (1989).
11. K. M. Jenkins and A. J. Vanderwielen, Cleaning validation: An overall perspective, Pharm. Technol., 18(4), 60-73 (1994).
12. B. T. Callan, Cytotoxic drug containment, Pharm. Eng., 14(6), 56-61 (1994).
13. J. A. Shea, W. F. Shamrock, C. A. Abboud, R. W. Woodeshick, L.-Q. S. Nguyen, J. T. Rubino, and J. Segretario, Validation of cleaning procedures for highly potent drugs. I. Losoxantrone, Pharm. Dev. Technol., 1(1), 69-75 (1996).
14. P. J. M. Sessink, R. B. Anzion, P. H. H. Van den Brock, and R. P. Bos, Detection of contamination with antineoplastic agents in a hospital pharmacy department, Pharm. Weekbl. (Sci.), 14(1), 16-22 (1992).
15. P. J. M. Sessink, K. A. Boer, A. P. H. Scheefhals, R. B. M. Anzion, and R. P. Bos, Occupational exposure to antineoplastic agents at several departments in a hospital, Int. Arch. Occup. Environ. Health, 64(2), 105-112 (1992).
16. P. J. M. Sessink, J. L. Timmersmans, R. B. M. Anzion, and R. P. Bos, Assessment of occupational exposure of pharmaceutical plant workers to 5-fluorouracil, J. Occup. Med., 36(1), 79-83 (1994).
17. K. D. Altria and T. A. Hadgett, An evaluation of the use of capillary electrophoresis to monitor trace drug residues following the manufacture of pharmaceuticals, Chromatographia, 40(1/2), 23-27 (1995).
18. L. Elrod Jr., J. L. Schmit, and J. A. Morley, Determination of isoproterenol sulfate on surfaces using high-performance liquid chromatography with electrochemical detection, J. Chromatogr. A, 723, 235-241 (1996).